MYC and esophageal cancer: In conclusion, these results support that aggressive esophageal cancer cells with elevated c-Myc expression are an effective targeting option for the CDK inhibitor flavopiridol, and flavopiridol alone or in combination with cytotoxic or targeted agents can be a potential option for high c-Myc expressing esophageal cancer therapy.